FuelCell Energy Inc (FCEL) Stock Price Today
Aura AI Summary
Key Stats
- $1.37BMarket Cap
- 3,435,674Volume
- IndustrialsSector
- $36.0152W High
- $6.0052W Low
- 47 DaysTypical Hold Time
- $953.51MEnterprise Value
- -Div Yield
- 38% Sell | 62% BuyTrading Activity
Track FuelCell Energy Inc (FCEL) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, FuelCell Energy Inc has traded between a low of $6 and a high of $36.01, highlighting its annual price range. Buy and sell FuelCell Energy Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About FuelCell Energy Inc
FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products, which efficiently convert chemical energy in fuels into electricity through a series of chemical reactions. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company generates a majority of its revenue from the United States followed by South Korea.
Most Recent News
BMO lowers Paychex price target to $113 after mixed earnings and slowing sales growth
BMO Capital analyst Daniel Jester lowered the price target for Paychex to $113, reflecting caution despite the company's slight earnings beat with $1.63 billion revenue and $1.34 non-GAAP EPS. The stock dropped 8.77% as investors focused on lower GAA...
General Mills sees 3% sales drop but beats earnings estimates with strong international growth.
General Mills reported a 3% decline in sales to $4.40 billion, partly due to selling its U.S. yogurt business, causing adjusted gross margin to fall to 33.3%. Despite this, the company beat earnings expectations with adjusted EPS of $0.75, helped by ...
Replimune faces securities lawsuit over alleged misleading FDA trial data claims on RP1 drug resubmission.
Investors have filed a securities class action against Replimune Group, alleging the company misled the market by claiming its RP1 drug resubmission fully addressed FDA concerns, despite the FDA stating the trial data was inadequate. The lawsuit high...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.